Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Posology Study With Long-Term Extension in Participants With Well-Controlled Recurrent Pericarditis to Evaluate the Efficacy and Safety of Transition Regimens to KPL-387 Monotherapy From Standard Therapies

NCT07288216 is registered in ClinicalTrials.gov with Kiniksa Pharmaceuticals International, plc as lead sponsor.

NCT NCT07288216
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07288216 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Posology Study With Long-Term Extension in Participants With Well-Controlled Recurrent Pericarditis to Evaluate the Efficacy and Safety of Transition Regimens to KPL-387 Monotherapy From Standard Therapies
Lead sponsor
Kiniksa Pharmaceuticals International, plc
Phase
Phase 2
Overall status
Recruiting
Start date
March 25, 2026
Completion date
December 31, 2029
Enrollment
120 (estimated)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

heart diseases, pericarditis, recurrent pericarditis